AVL-292 is a covalently bound, orally available and highly selective BTK inhibitor with an IC50 of less than 0.5 nM, demonstrating at least 1400 times more selectivity than other tested kinases. AVL-292 showed dose-dependent inhibition of BTK in Ramos cells with EC50 of 8 nM. And the downstream BCR pathway is inhibited. AVL-292 further inhibited the proliferation of B cells by inhibiting the activity of BTK, and its EC50 was 3 nM.

 

Brand: BCM

 

pKa: 13.22±0.70(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water and Ethanol.

 

Attribute
[CAS No.]	1202757-89-8
[Formula]	C22H22FN5O3
[Molecular]	423.44
[Chem Name]	N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide
[Synonym]	CC-292; AVL-292; Spebrutinib
[Storage]	Sealed in dry. 2-8°C
[MDL No.]	MFCD25976876
[Form]	Solid

Goods Tag